Brief: Ovoca Bio Posts Summary Results Of Phase II Study For Orenetide

Talisman Metals

31/08/2023 07:21

Aug 31 (Reuters) - Ovoca Bio PLC  OVB.L :
    * OVOCA BIO PLC  - SUMMARY RESULTS OF PHASE II STUDY FOR
ORENETIDE
    * OVOCA BIO - SUMMARY CONCLUSION OF TOP-LINE RESULTS FROM
ITS
PHASE II DOSE RANGING STUDY ASSESSING ORENETIDE CONDUCTED IN
AUSTRALIA & NEW ZEALAND
    * OVOCA BIO - SAFETY PROFILE OF ORENETIDE OBSERVED IN STUDY
WAS
CONSISTENT WITH PREVIOUSLY KNOWN SAFETY PROFILE, & NO NEW SAFETY
SIGNALS WERE IDENTIFIED
    * OVOCA BIO PLC - STUDY DID NOT SHOW STATISTICALLY
SIGNIFICANT
SUPERIORITY OF ORENETIDE VERSUS PLACEBO ON CO-PRIMARY ENDPOINTS
    * OVOCA BIO PLC - OTHER SECONDARY EFFICACY ENDPOINTS WERE
ALSO
SHOWN NOT TO HAVE STATISTICALLY SIGNIFICANT DIFFERENCE VERSUS.
PLACEBO

Source text for Eikon:  ID:nRSe8586Ka 
Further company coverage:  OVB.L